P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer ; volume:2 ; number:2 ; day:12 ; month:3 ; year:2014 ; pages:1 ; date:3.2014
Journal for ImmunoTherapy of Cancer ; 2, Heft 2 (12.3.2014), 1, 3.2014
- Creator
-
Jallad, S.
- Contributor
-
Thomas, P.
Newport, M.
Kern, F.
SpringerLink (Online service)
- DOI
-
10.1186/2051-1426-2-S2-P32
- URN
-
urn:nbn:de:1111-2016072657381
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jallad, S.
- Thomas, P.
- Newport, M.
- Kern, F.
- SpringerLink (Online service)
Other Objects (12)
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Protective role of intravesical BCG in COVID-19 severity
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
A solitary pulmonary nodule caused by Mycobacterium tuberculosis var. BCG after intravesical BCG treatment: a case report
Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer
Bacille Calmette-Guérin (BCG) spondylitis with adjacent mycotic aortic aneurysm after intravesical BCG therapy: a case report and literature review
Correction to: Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
Culture-proven disseminated Mycobacterium Bovis infection (BCG-Osis) following intravesical BCG immunotherapy in a patient with bladder carcinoma-in-situ: ‘Case report’
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial
Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Protective role of intravesical BCG in COVID-19 severity
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
A solitary pulmonary nodule caused by Mycobacterium tuberculosis var. BCG after intravesical BCG treatment: a case report
Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer
Bacille Calmette-Guérin (BCG) spondylitis with adjacent mycotic aortic aneurysm after intravesical BCG therapy: a case report and literature review
Correction to: Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
Culture-proven disseminated Mycobacterium Bovis infection (BCG-Osis) following intravesical BCG immunotherapy in a patient with bladder carcinoma-in-situ: ‘Case report’
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial
Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Protective role of intravesical BCG in COVID-19 severity
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
A solitary pulmonary nodule caused by Mycobacterium tuberculosis var. BCG after intravesical BCG treatment: a case report
Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer
Bacille Calmette-Guérin (BCG) spondylitis with adjacent mycotic aortic aneurysm after intravesical BCG therapy: a case report and literature review
Correction to: Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
Culture-proven disseminated Mycobacterium Bovis infection (BCG-Osis) following intravesical BCG immunotherapy in a patient with bladder carcinoma-in-situ: ‘Case report’
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial